RxDoctor Payments Data

Terri Kemmerer

Family · Gainesville, GANPI 1013199587

Payments from drug & device makers

$5,603in general payments, 2019–2025

Across 89 payments — averaging $62.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$810
  • Medtronic$616
  • Novo Nordisk$547
  • AstraZeneca$545
  • Sanofi-aventis U.S. LLC$454
  • Boehringer Ingelheim$291
  • plus $2K from 18 others

What the payments were for

  • Travel & lodging$230%
  • Food & beverage$5,53899%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,603 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide231$261,485
OzempicSemaglutide151$194,336
JardianceEmpagliflozin78$96,606
Tresiba Flextouch U-200Insulin Degludec36$80,012
Tresiba Flextouch U-100Insulin Degludec77$70,876
TrulicityDulaglutide44$63,313
FarxigaDapagliflozin Propanediol48$53,201
RybelsusSemaglutide24$50,211
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/723$36,167
Soliqua 100-33Insulin Glargine/Lixisenatide25$24,481
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog16$18,061
JanuviaSitagliptin Phosphate12$18,006
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$16,469
NovologInsulin Aspart40$13,845
Novolog FlexpenInsulin Aspart53$12,343

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog$264$331,442296 claims
Novo NordiskOzempic, Rybelsus, Novolog$547$258,392215 claims
Boehringer IngelheimJardiance, Synjardy$291$107,47090 claims
AstraZenecaFarxiga$545$53,20148 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$454$24,48125 claims
AbbVieSynthroid$132$5,04557 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →